The Sanofi India stock hit fresh highs on Wednesday, after it posted a better-than-expected December quarter (Q3) performance. Revenue growth continues to be driven by a large branded portfolio in the high-growth chronic segment. The tilt towards the more-profitable chronic segment, coupled with a leadership position in diabetes therapy, gives it an edge over its peers.
Revenues in Q3 grew 14 per cent year-on-year (YoY). The top five products have contributed about 57 per cent to revenues, and are likely to drive future growth, say analysts. Top brands like Lantus for diabetes, ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
First Published: Wed, February 26 2020. 23:05 IST
